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Rheumatic fever: New ideas 
in diagnosis and management
should lend itself to the development of biomarkers. (“Biological 
characteristics that can be objectively measured and evaluated as 
an indicator of normal biological processes, pathogenic processes, 
or pharmacological responses to a therapeutic intervention that 
refine the diagnosis of the disease”.)(2) 
Apparently there appear to be very few other processes that can 
damage the mitral or aortic valve of the younger patient. Esta-
blished changes are relatively easy to recognise as being typical of 
rheumatic heart disease. However, there are consequences of 
under-diagnosis of cardiac involvement (inadequate duration of 
prophylaxis) or incorrect diagnosis (labelling congenital disease or 
physiological regurgitation as rheumatic heart disease). It remains 
equally important to be able to identify the patient with acute 
rheumatic fever without cardiac disease in the group of patients 
seen with febrile illnesses and arthritis. 
What is the current understanding of the disease’s pathogenesis? 
To paraphrase a recent publication:(3) A Group A streptococcus 
which is “rheumatogenic” has to affect a susceptible individual 
(genetic/environmental risks) and this is then followed by a complex 
immune process (again modulated by genetic influences). 
The author of this paper have attempted to summarise current 
knowledge on the genetic susceptibility to acute rheumatic fever 
and rheumatic heart disease. 
It is unclear whether some of the various genetic markers of risk 
such as HLA typing or B cell markers are epiphenomena or true 
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RHEUMATIC FEVER
IntroductIon                                                              
In the minds of many practitioners in the developed world, 
rheumatic fever is an old and vanishing disease. Diagnosis is framed 
in the revered Jones criteria and treatment rests with a simple drug 
that is difficult to buy in modern commercial pharmacies. In reality, 
rheumatic heart disease disables young adults and shortens their 
lives in many parts of the world. Sadly though, even in developing 
countries the clinical recognition of acute rheumatic fever can be 
inaccurate.(1) 
T. Duckett Jones (whose criteria were first used in 1944) deserves 
credit for establishing a set of clinical rules that with relatively few 
modifications are still the gold standard for the diagnosis. These 
rules have a number of major weaknesses, one being their applica-
tion to diagnose recurrences in areas of high prevalence of 
rheumatic heart disease. Another weakness is the lack of specificity 
in areas of low prevalence.
 
Why has a new diagnostic test for acute rheumatic fever not 
emerged yet? The pathological consequences of the process 
(typified by the Aschoff nodule) are remote and not easily acces-
sible in the patient. The pathogenesis of the disease is not 
straightforward. However, increasing understanding of the process 
rheumatic heart disease remains a major cause of disability 
and death in developing countries. careful re-analysis of mid- 
20th century data  as well as the juxtaposition of well-funded 
research units and populations at risk have generated 
information that resulted in radical departures from standard 
approaches to the prevention, clinical recognition and 
treatment of acute rheumatic fever. As a result,  rheumatic 
heart disease may be eliminated in the future.   
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pointers to populations at risk. In other words, are these 
abnormalities (such as the increased incidence HLA DR 1 and 6 
described in South Africans with rheumatic heart disease)(4) part of 
the pathogenesis of the disease or flags for other components of 
the complex pathogenesis?
Adding to this uncertainty, HLA markers vary from country to 
country. The D8/17 lymphocyte subset is said to be increased in 
most populations with rheumatic heart disease(3) but our own 
experience with the D8/17 B cell subpopulations in patients with 
rheumatic heart disease is totally different.(5) The pathogenesis of 
the acute stadium involves molecular mimicry and all components 
of the immune system. While the streptococcal pharyngitis is still 
regarded as the main triggering infection, streptococcal skin infec-
tions may also have some influence.(6)  
Three percent of individuals who are exposed to pathogenic 
streptococci will develop rheumatic fever in their lifetime. Three 
percent of individuals with a symptomatic sore throat during 
epidemics will develop acute rheumatic fever. Carapetis et al.(7) 
point out that this rate is fairly similar to  rates in North America 
at the start of the 20th century, thus the contributions of a 
“genetic” component to the development of rheumatic fever need 
to be judged in this light. 
Anecdotally the number of patients admitted to facilities in Cape 
Town with acute rheumatic fever appears to be decreasing; yet 
rheumatic heart disease remains a problem. Why so? Is there a true 
decline in acute rheumatic fever or has the recognition of the 
condition become poorer during the recent AIDS epidemic?
Parks and colleagues were able to show (by retrospectively analysing 
patient records) that the recognition of acute rheumatic fever at 
primary care facilities in Fiji was very poor.(8)  Their work is disturbing 
given the high prevalence of rheumatic heart disease in that area 
as well as the lack of other major epidemic illnesses which might 
be confused with rheumatic fever. 
the jIgsAw puzzle of pAthogenesIs:                     
how could It AId In dIAgnosIs And                    
mAnAgement? 
A better understanding of the disease (including the accurate 
identification of the disease-causing streptococci) could help in the 
following ways:
By defining a group at risk, the use of primary prophylaxis ■
and/or vaccination would be appropriate given the risks of 
unchecked antibiotic use and the theoretical risks of vaccine 
use. Similarly, these preventative regimens could be extended 
to family members of patients with rheumatic heart disease.
Alternative concepts of the triggering of the disease, such as 
the role of skin infections as a primer could be tested and 
therapies directed specifically at those triggers.  
The combination of biomarker estimation, echocardiography 
and clinical criteria would allow the development of a set of 
“super criteria” for the diagnosis of acute rheumatic fever 
avoiding over-diagnosis in patients with arthritis and fever due 
to other illnesses or mild valvular prolapse and a febrile illness. 
The recognition of subgroups at risk for cardiac involvement 
during an acute attack would allow tailored secondary 
prophylaxis regimens to be instituted.
The recognition of subtle cardiac involvement during an attack 
either using a biomarker or a tested echocardiographic screen-
ing protocol would also allow structured use of secondary 
prophylaxis regimens. 
An accurate model of the pathophysiology leading to cardiac 
and neurological structural damage would allow tailored treat-
ment of carditis and chorea by immuno-modulatory therapies. 
the current stAtus of prImAry                              
preventIon And vAccInAtIon
A successful vaccine against Group A streptococcal infection 
would have the benefit of decreasing the prevalence of rheu- 
matic heart disease as well as other sequelae of infection such as 
invasive disease. Initial attempts at developing a vaccine against 
group A streptococcal infection failed when vaccinated subjects 
developed acute rheumatic fever after vaccination.(9) Despite a 
better understanding of vaccine design the authors of a recent 
paper expressed disappointment that only one vaccine has been 
studied clinically in the last 3 decades.(10)  The accurate identification 
of the multiple serotypes causing acute rheumatic fever in various 
parts of the globe has raised concerns regarding the potential 
effectiveness of the current multivalent vaccine.(11)
The differentiation of a “strep throat” from an episode of viral 
pharyngitis remains difficult. Furthermore, confirmation by culture 
or other techniques remains unlikely in resource poor communi-
ties. Indeed, under recognition and underreporting of sore throats 
is probably responsible for the well-recognised lack of a history of 
■
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Although there is evidence that 2-weekly prophylaxis is more 
effective than 4-weekly treatments in some countries there appears 
to be little advantage in administering penicillin more frequently 
than every 4 weeks unless a patient has breakthrough attacks.(21) 
Intra-muscular penicillin is also recommended in some populations 
for patients taking oral anticoagulants.(22) Paradoxically, intra-
muscular penicillin is an orphan drug in some major centres in 
South Africa with preparations available in State facilities but not in 
private pharmacies. The incidence of anaphylaxis is very low.(23) 
The injection however remains painful and continued adherence 
is facilitated by a close relationship between practitioner and 
patient. A recent study in the Pacific’s Northern Mariana Islands 
confirmed that poor adherence to prophylaxis offers no advant- 
age over no prophylaxis with respect to prevention of acute 
attacks.(24) Various culturally appropriate methods (lunar calendars 
for rural Australians, cell phone text message reminders for 
Fijians) are used in an effort to improve adherence. 
The duration of secondary prophylaxis varies from country 
to country. World Health Organisation (WHO) guidelines for 
example suggest that prophylaxis should be continued until 25 
years of age or ten years after the last episode of carditis occur- 
red.(25) The New Zealand guidelines suggest that prophylaxis 
should be continued until the age of 30 years if carditis is 
present.(22) Guidelines for South African patients are currently 
being developed. 
A unIfIed strAtegy to reduce Acute                    
rheumAtIc fever
Several experts(15,22) have argued that the incidence of acute 
rheumatic fever and rheumatic heart disease have decreased in 
populations after the application of a comprehensive set of strate-
gies including both primary and secondary prevention and educa-
tion. Unfortunately,  many areas of the world ridden with  rheumatic 
heart disease, there are no statistics on the incidence of acute 
rheumatic fever as well as the prevalence of rheumatic heart 
disease. Efforts to establish a series of worldwide registries (to 
remedy the lack of data) are currently underway. 
It is sobering to note that the decline in acute rheumatic fever 
deaths in the United States that occurred in the early part of 
the twentieth century occurred without the use of penicillin. This 
sore throat in patients with documented episodes of acute 
rheumatic fever as well as the presentation of young adults with 
established rheumatic heart disease and no preceding history of 
acute rheumatic fever. 
The available evidence on penicillin  treatment of all patients with 
pharyngitis with suspected streptococcal sore throat has been 
reviewed in a meta-analysis,(12) treatment was associated with a 
positive benefit in so far as  episodes of acute rheumatic fever were 
prevented. It has been suggested from work in Costa Rica(13) and 
Cuba(14) that treatment of all patients with a suspected streptococ-
cal sore throat with penicillin is beneficial. This is controversial.(15) 
The existing body of work suffers from a lack of controlled trials, 
apart from a trial from New Zealand (see below) as well as 
clinical decision rules which vary from loose to strict in terms of 
deciding which patients had streptococcal sore throat.
A recent randomised control trial in New Zealand could not 
show any benefit in the nurse-led treatment of streptococcal sore 
throats in terms of the prevention of acute rheumatic fever.(16) 
Concern has been expressed that the control group in this study 
may not have been “pure” in terms of access to primary health 
care and oral penicillin therapy.(17) 
The distinction of “streptococcal” from “viral” sore throats on 
clinical grounds is difficult. The use of clinical algorithms has be 
shown to reduce the unnecessary administration of antibiotics – 
even preventative programmes which use the weakest algorithms 
are likely to be successful.(18) 
secondAry preventIon strAtegIes                    
For the contemporary practitioner, each meta-analysis of past 
research yields surprises. The often-repeated criticism of these 
analyses is that past studies were not performed with modern 
rigour and that archaic forms of modern drugs were used. 
Nevertheless, standard practices are constantly being challenged. 
For example: It is disappointing to realise that though there is 
evidence that secondary prophylaxis reduces the incidence of 
second attacks of acute rheumatic fever, the assumption that this 
reduction will coincide with a reduction in cardiac damage is 
probably not true.(19) The standard for prophylaxis is an intra-
muscular penicillin injection rather than oral prophylaxis.(20) 
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could probably be ascribed to an improvement in the average 
living conditions and a decline in the virulence of the causative 
organisms.(26)
the Acute epIsode – dIAgnosIs In 2010                    
The Duckett Jones criteria have been revised several times to 
track the drop in the occurrence of acute rheumatic fever in the 
USA.(27) Paradoxically the tightening of criteria has potentially 
decreased the diagnosis of acute rheumatic fever in high risk po-
pulations. Modifications of the 1992 revision have been adopted 
by the WHO to allow for the diagnosis of a recurrence of rheu-
matic fever in patients with established rheumatic heart disease as 
well as the diagnosis of indolent carditis.(25) The WHO guidelines 
below (Figure 1) explains the modifications by themselves as well 
as the Australian Health Assocation (AHA) in graphical form. 
In the Australian experience, decreasing the threshold for the 
definition of fever to 38° instead of 39° increased the sensitivity of 
the diagnosis.(28)  
In recent years it has been suggested that higher “local values” 
for abnormal ASO and anti-DNAse B titres should be established 
given the assumption that poorer populations were more often 
exposed to streptococcal infections. This belief has been chal- 
lenged by the work of Steer and his colleagues in Fiji, suggesting 
that the “upper limits of normal” for such titres are not markedly 
different between populations. (For example, a “cut-off ” value of 
276 IU/ml for ASOT and 499IU/ml for anti-DNAse B for the age 
range of 5-15 years is suggested).(29)
The widespread use of echocardiography in patients with acute 
rheumatic fever has resulted in the recognition of subclinical carditis 
in up to 16% of patients.(30) In Australia and New Zealand, sub-
clinical carditis has been added to the major criteria.(22) Standards 
for the diagnosis of carditis using echocardiography have been 
developed in New Zealand;(31) there are, however, differences 
reported in the literature as to the extent of documented valvular 
damage in patients with subclinical carditis. Subclinical carditis is 
being associated with more florid valvular change in patients from 
the Indian subcontinent.(32)  “Echo-detected” carditis has not been 
fIgure 1: Changes in the Jones criteria following review from AHA and WHO
PR: PR interval in the electrocardiogram, WBC: leukcoytosis, ESR: erythrocyteseyimontation rate, CRP: C-reactive protein.
Carditis
Long PR
Arthritis
Arthralgia
Subcutaneous nodules
Chorea
Erythena marginaturn
Pre-existing RF/RHD
Fever WBC, ESC, CRP
Epistaxis, abdominal 
pain, anemia, 
pulmonary findings
Recent streptococcal 
infection
Manifestations Original Jones 
criteria
1944
AHA 
modified
1956
AHA
revised
1965 (1984)
WHO
1988
AHA 
update
1992
WHO
2003
Essential                    Major                    Minor                    Special consideration
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other diseases such as myocarditis are used  in desperation despite 
lack of evidence for efficacy. 
In patients with carditis and severe valvular involvement, standard 
anti-failure therapy including the use of modern vasodilators is 
recommended. A trial of immunoglobulin therapy had a negative 
outcome.(43) Valve replacement in severely affected individuals 
may be life saving. Recent work from New Zealand indicated 
that good valve repairs are possible in the aftermath of an acute 
attack but that the durability is affected by the presence of 
endocardial inflammation.(21)
The results of a trial of immunoglobulin therapy in chorea from 
our own institution are pending; this study and other data have 
reinforced our impression that chorea is a potentially debilitating 
and chronic condition and that the effective treatment of this 
condition is tricky. For example: Significantly reduced doses of 
haloperidol than recommended in the standard texts should 
be used to avoid extra-pyramidal side effects. (Starting dose: 
0.025 mg/kg/day in divided doses increased slowly to a maximum 
of 0.05mg/kg/day.) Alternatives include sodium valproate or 
pimozide. The practitioner treating the patient with Sydenham’s 
chorea must remember to eradicate the streptococcus as well. 
conclusIon                                                                    
The application of modern scientific techniques has destroyed 
the apparent simplicity of approaches to the prevention and 
management of acute rheumatic fever and its sequelae developed 
in the 20th century. Current practice should aim to improve the 
recognition of streptococcal sore throat at primary care level. 
It should ensure that both primary and secondary prophylaxis 
occurs in populations at risk in an effective manner while consi-
dering local circumstances. International cooperation both in 
terms of the establishment of registries as well as multicentre 
trials should be encouraged. 
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added to the proposed South African standards for the diagnosis 
of acute rheumatic fever. 
New Zealand patients with mono-arthritis are considered to have 
the arthritis of acute rheumatic fever if they have used non- 
steroidal anti-inflammatory agents to relieve pain. (Practitioners 
are encouraged to use paracetamol rather than NSAIDs to treat 
patients with mono-arthritis).(33) 
In populations with a high prevalence of disease, doubt has been 
expressed as to the existence of isolated arthritis following a 
streptococcal infection as well as to the existence of a separate 
category of neurological conditions known as PANDAS (paediatric 
auto-immune neuropsychiatric disorder).(33) 
The existence of a separate myocarditis in patients with carditis 
has been disproved using sophisticated echo techniques as well 
by measuring serum troponin levels.(34,35) BNP measurement has 
been helpful to differentiate those patients with carditis from those 
without valvular involvement.(36) QT dispersion is also abnormal in 
those with carditis.(37)
Chorea has classically been regarded as an isolated phenomenon; 
however in our own patients chorea is associated with carditis in 
half of the patients.(38)  
mAnAgement of An epIsode of Acute                  
rheumAtIc fever
Revisiting older literature has cast doubts on standard aspects of 
acute care such as bed rest and aspirin use.(39) In my opinion, 
bed rest is a useful surrogate for warmth, good food and freedom 
from the household chores and challenges that typify life for a 
poor child. Recent work from Turkey documented differences in 
bio-elements and vitamins with antioxidant functions between 
patients with acute rheumatic fever and control groups, thus 
the possibility exists that dietary manipulation might modify 
outcomes.(40)
There is no evidence that aspirin and corticosteroids play any 
role in the management of the inflammatory component of 
acute rheumatic fever.(41) Aspirin as an analgesic for arthritis is still 
recommended therapy, yet we do not  use aspirin in other forms 
of arthritis. There is some data to suggest that naproxen is an 
effective agent to relieve joint pain.(42) Corticosteroids used in 
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